A cancer thriver reflects on the emotional toll, survivorship, advocacy and support networks they wish they’d known at ...

Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

A beloved former college basketball star has died from cancer at 49 years old. Larry Florence, a legendary Nebraska ...

By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...

Brightpath Biotherapeutics Co. Ltd.’s iPS cell-derived BCMA CAR-natural killer T cell therapy candidate has been awarded orphan drug designation by the FDA for the treatment of multiple myeloma.

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

CAR T-cell therapy is starting to enter the treatment conversations sooner with patients with multiple myeloma, according to ...

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.